Vascular and Metabolic Effects of Combined Therapy With Ramipril and Simvastatin in Patients With Type 2 Diabetes
- 1 June 2005
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Hypertension
- Vol. 45 (6) , 1088-1093
- https://doi.org/10.1161/01.hyp.0000166722.91714.ba
Abstract
Mechanisms underlying biological effects of statin and angiotensin-converting enzyme inhibitor therapies differ. Therefore, we compared vascular and metabolic responses to these therapies either alone or in combination in patients with type 2 diabetes. This was a randomized, double-blind, placebo-controlled crossover trial with 3 treatment arms (each 2 months) and 2 washout periods (each 2 months). Fifty patients with type 2 diabetes were given simvastatin 20 mg and placebo, simvastatin 20 mg and ramipril 10 mg, or ramipril 10 mg and placebo daily during each 2-month treatment period. Ramipril alone or combined therapy significantly reduced blood pressure when compared with simvastatin alone. When compared with ramipril alone, simvastatin alone or combined therapy significantly improved the lipoprotein profile. All 3 treatment arms significantly improved flow-mediated dilator response to hyperemia and reduced plasma levels of malondialdehyde relative to baseline measurements. However, these parameters wer...Keywords
This publication has 29 references indexed in Scilit:
- Additive Beneficial Effects of Losartan Combined With Simvastatin in the Treatment of Hypercholesterolemic, Hypertensive PatientsCirculation, 2004
- Simvastatin Combined With Ramipril Treatment in Hypercholesterolemic PatientsHypertension, 2004
- Adiponectin Stimulates Production of Nitric Oxide in Vascular Endothelial CellsJournal of Biological Chemistry, 2003
- C-Reactive Protein Upregulates Angiotensin Type 1 Receptors in Vascular Smooth MuscleCirculation, 2003
- Simvastatin Prevents Angiotensin II–Induced Cardiac Alteration and Oxidative StressHypertension, 2002
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialPublished by Elsevier ,2002
- Effects of Diet and Simvastatin on Serum Lipids, Insulin, and Antioxidants in Hypercholesterolemic MenJAMA, 2002
- Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk PatientsNew England Journal of Medicine, 2000
- Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk.Journal of Clinical Investigation, 1997
- A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non—Insulin-dependent diabetes mellitus and hyperlipoproteinemiaMetabolism, 1995